Fibronectin type iii domain proteins with enhanced solubility
AssigneeBristol-Myers Squibb Company
InventorsAaron P. YAMNIUK, Stanley R. KRYSTEK
Life of this patent
Estimating the term…
Abstract
Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.
Claims15
1-40. (canceled)
A nucleic acid encoding a polypeptide comprising a 10th human fibronectin type III (10Fn3) domain, wherein the amino acid in the 10Fn3 domain corresponding to residue 58 of SEQ ID NO:
- 1 is Glu (E), and wherein the solubility of the 10Fn3 domain is enhanced relative to the solubility of the same 10Fn3 domain wherein the amino acid corresponding to residue 58 of SEQ ID NO:
- 1 is Thr (T).
A method of treating a disease or disorder comprising administering to a subject in need thereof a polypeptide comprising a 10th human fibronectin type III (10Fn3) domain, wherein the amino acid in the 10Fn3 domain corresponding to residue 58 of SEQ ID NO:
- 1 is Glu (E), and wherein the solubility of the 10Fn3 domain is enhanced relative to the solubility of the same 10Fn3 domain wherein the amino acid corresponding to residue 58 of SEQ ID NO:
- 1 is Thr (T).
A composition comprising a polypeptide comprising a 10th human fibronectin type HI (10Fn3) domain, wherein the amino acid in the 10Fn3 domain corresponding to residue 58 of SEQ ID NO:
- 1 is Glu (E), and wherein the solubility of the 10Fn3 domain is enhanced relative to the solubility of the same 10Fn3 domain wherein the amino acid corresponding to residue 58 of SEQ ID NO:
- 1 is Thr (T).
Dependencies are inferred from the claim text.